An in vitro method for (a) inducing differentiation of CNS progenitor / precursor cells into CNS cells, (b) improving proliferation of CNS cells or CNS progenitor / precursor cells, or (c) improving survival of CNS cells or CNS progenitor / precursor cells, comprising contacting said cells with a BRD7 antagonist, or an Ikaros antagonist, wherein the BRD7 antagonist is selected from a group consisting of: (i) an inhibitor of BRD7 protein, wherein the inhibitor of BRD7 protein is: an inhibitor of BRD7 production, an inhibitor of BRD7 action, or a nucleic acid comprising a coding region of an inhibitor of BRD7; (ii) a nucleic acid comprising at least part of nucleic acid sequence of BRD7 gene, wherein the nucleic acid is: an antisense molecule specific to a BRD7 gene, an RNAi molecule, or a Morpholino oligonucleotide specific to BRD7 gene; and (iii) a stem cell, induced pluripotent stem cell, neural progenitor cell, or neural precursor cell in which BRD7 is down-regulated; and wherein the antagonist of Ikaros is selected from a group consisting of: (i) an inhibitor of Ikaros protein, wherein the inhibitor of Ikaros is: an inhibitor of Ikaros production, an inhibitor of Ikaros action, or a nucleic acid comprising a coding region of an inhibitor of Ikaros; (ii) a nucleic acid comprising at least part of nucleic acid sequence of Ikaros gene, wherein the nucleic acid is: an antisense molecule specific to an Ikaros gene, an RNAi molecule, or a Morpholino oligonucleotide specific to Ikaros gene; and (iii) a stem cell, induced pluripotent stem cell, neural progenitor cell, or neural precursor cell in which Ikaros is down-regulated. wherein the BRD7 antagonist is selected from a group consisting of: (i) an inhibitor of BRD7 protein, wherein the inhibitor of BRD7 protein is: an inhibitor of BRD7 production, an inhibitor of BRD7 action, or a nucleic acid comprising a coding region of an inhibitor of BRD7; (ii) a nucleic acid comprising at least part of nucleic acid sequence of BRD7 gene, wherein the nucleic acid is: an antisense molecule specific to a BRD7 gene, an RNAi molecule, or a Morpholino oligonucleotide specific to BRD7 gene; and (iii) a stem cell, induced pluripotent stem cell, neural progenitor cell, or neural precursor cell in which BRD7 is down-regulated; and (i) an inhibitor of BRD7 protein, wherein the inhibitor of BRD7 protein is: an inhibitor of BRD7 production, an inhibitor of BRD7 action, or a nucleic acid comprising a coding region of an inhibitor of BRD7; an inhibitor of BRD7 production, an inhibitor of BRD7 action, or a nucleic acid comprising a coding region of an inhibitor of BRD7; (ii) a nucleic acid comprising at least part of nucleic acid sequence of BRD7 gene, wherein the nucleic acid is: an antisense molecule specific to a BRD7 gene, an RNAi molecule, or a Morpholino oligonucleotide specific to BRD7 gene; and an antisense molecule specific to a BRD7 gene, an RNAi molecule, or a Morpholino oligonucleotide specific to BRD7 gene; (iii) a stem cell, induced pluripotent stem cell, neural progenitor cell, or neural precursor cell in which BRD7 is down-regulated; wherein the antagonist of Ikaros is selected from a group consisting of: (i) an inhibitor of Ikaros protein, wherein the inhibitor of Ikaros is: an inhibitor of Ikaros production, an inhibitor of Ikaros action, or a nucleic acid comprising a coding region of an inhibitor of Ikaros; (ii) a nucleic acid comprising at least part of nucleic acid sequence of Ikaros gene, wherein the nucleic acid is: an antisense molecule specific to an Ikaros gene, an RNAi molecule, or a Morpholino oligonucleotide specific to Ikaros gene; and (iii) a stem cell, induced pluripotent stem cell, neural progenitor cell, or neural precursor cell in which Ikaros is down-regulated. (i) an inhibitor of Ikaros protein, wherein the inhibitor of Ikaros is: an inhibitor of Ikaros production, an inhibitor of Ikaros action, or a nucleic acid comprising a coding region of an inhibitor of Ikaros; an inhibitor of Ikaros production, an inhibitor of Ikaros action, or a nucleic acid comprising a coding region of an inhibitor of Ikaros; (ii) a nucleic acid comprising at least part of nucleic acid sequence of Ikaros gene, wherein the nucleic acid is: an antisense molecule specific to an Ikaros gene, an RNAi molecule, or a Morpholino oligonucleotide specific to Ikaros gene; and an antisense molecule specific to an Ikaros gene, an RNAi molecule, or a Morpholino oligonucleotide specific to Ikaros gene; (iii) a stem cell, induced pluripotent stem cell, neural progenitor cell, or neural precursor cell in which Ikaros is down-regulated.